Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00452140
Status:
TERMINATED
Last Update Posted:
2009-05-19
First Post:
2007-03-26
Brief Title:
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment
Sponsor:
Neovii Biotech
Organization:
Neovii Biotech
Organization Data
Organization:
Neovii Biotech
Class:
INDUSTRY
Study ID:
IV-ERT-BC-03
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Neovii Biotech
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Fresenius Biotech GmbH
Old Organization:
Fresenius Biotech GmbH